Role of renin-angiotensin system in gastric oncogenesis

Mitsushige Sugimoto1, Yoshio Yamaoka, Naohito Shirai

  • 1First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, Japan. mitsu@hama-med.ac.jp

Insights

The renin-angiotensin system (RAS) is linked to cancer development, particularly in H. pylori-infected stomachs. RAS inhibitors may offer a new strategy for preventing gastric cancer.

Area of Science:

  • Oncology
  • Cardiovascular Research
  • Gastroenterology

Background:

  • The renin-angiotensin system (RAS) is crucial for homeostasis and implicated in carcinogenesis.
  • Hypertension and upregulated RAS are associated with increased cancer risk and poor outcomes.
  • RAS inhibitors have shown potential in reducing tumor development, progression, and metastasis.

Purpose of the Study:

  • To investigate the association between Helicobacter pylori infection, RAS component expression, and gastric carcinogenesis.
  • To explore the role of RAS in the pathogenesis of H. pylori-related gastric cancer.
  • To evaluate the potential of RAS inhibitors in gastric cancer prevention.

Main Methods:

  • Review of epidemiological studies linking hypertension, RAS, and cancer risk.
  • Analysis of studies on H. pylori infection and its effect on RAS component expression in gastric mucosa.
  • Examination of findings on RAS genotypic variations and their relation to gastric cancer risk.

Main Results:

  • H. pylori infection leads to overexpression of RAS components (angiotensin I, II, ACE, AT1R) in the gastric mucosa.
  • Gastric RAS expression and activity increase with H. pylori infection duration and inflammation severity.
  • RAS genotypic variations correlate with higher component expression and increased gastric cancer risk.

Conclusions:

  • The RAS is significantly associated with the pathogenesis of H. pylori-related gastric carcinogenesis.
  • RAS component expression and activity are key factors in gastric carcinogenic potential.
  • RAS inhibitors represent a promising therapeutic strategy for preventing H. pylori-induced gastric cancer.

Related Concept Videos

Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...